Log in

Enzo Biochem Stock Forecast, Price & News

0.00 (0.00 %)
(As of 09/24/2020 12:00 AM ET)
Today's Range
Now: $2.09
50-Day Range
MA: $2.30
52-Week Range
Now: $2.09
Volume224,941 shs
Average Volume811,103 shs
Market Capitalization$100.09 million
P/E RatioN/A
Dividend YieldN/A
Enzo Biochem, Inc., an integrated diagnostic bioscience company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates in three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment manufactures, develops, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis to life science researchers. This segment provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment provides routine and esoteric clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication levels, or search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of approximately 30 patient service centers in New York and New Jersey; and a free standing 'STAT' or rapid response laboratory in New York City, as well as a full-service phlebotomy department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. The company markets its products and services through its direct sales force and a network of distributors in the United States and internationally. Enzo Biochem, Inc. was founded in 1976 and is headquartered in New York, New York.
Read More
Enzo Biochem logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.70 out of 5 stars

Industry, Sector and Symbol

Industry Medical laboratories



Sales & Book Value

Annual Sales$81.17 million
Book Value$1.81 per share


Net Income$2.49 million


Market Cap$100.09 million
Next Earnings Date10/20/2020 (Estimated)
0.00 (0.00 %)
(As of 09/24/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ENZ News and Ratings via Email

Sign-up to receive the latest news and ratings for ENZ and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Enzo Biochem (NYSE:ENZ) Frequently Asked Questions

How has Enzo Biochem's stock price been impacted by Coronavirus (COVID-19)?

Enzo Biochem's stock was trading at $2.86 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ENZ shares have decreased by 26.9% and is now trading at $2.09.
View which stocks have been most impacted by COVID-19

When is Enzo Biochem's next earnings date?

Enzo Biochem is scheduled to release its next quarterly earnings announcement on Tuesday, October 20th 2020.
View our earnings forecast for Enzo Biochem

How were Enzo Biochem's earnings last quarter?

Enzo Biochem, Inc. (NYSE:ENZ) announced its earnings results on Tuesday, October, 15th. The medical research company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.03. The medical research company earned $20.92 million during the quarter. Enzo Biochem had a negative net margin of 39.50% and a negative return on equity of 36.23%.
View Enzo Biochem's earnings history

Who are some of Enzo Biochem's key competitors?

What other stocks do shareholders of Enzo Biochem own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Enzo Biochem investors own include Onelife Technologies (OLMM), Gilead Sciences (GILD), Opko Health (OPK), Teva Pharmaceutical Industries (TEVA), Inovio Pharmaceuticals (INO), AbbVie (ABBV), Pfizer (PFE), Advanced Micro Devices (AMD), Amarin (AMRN) and Micron Technology (MU).

Who are Enzo Biochem's key executives?

Enzo Biochem's management team includes the following people:
  • Dr. Elazar Rabbani, Co-Founder, Chairman, CEO & Sec. (Age 76)
  • Mr. Barry W. Weiner, Co-Founder, Pres, CFO, Principal Accounting Officer, Treasurer & Director (Age 69)
  • Mr. James Michael O'Brien, Exec. VP of Fin. (Age 53)
  • Dr. Dieter Schapfel, Chief Medical Director - Enzo Clinical Labs (Age 56)
  • Mr. Bruce A. Dey, VP of Sales & Marketing - Enzo Clinical Labs (Age 61)

What is Enzo Biochem's stock symbol?

Enzo Biochem trades on the New York Stock Exchange (NYSE) under the ticker symbol "ENZ."

Who are Enzo Biochem's major shareholders?

Enzo Biochem's stock is owned by a variety of institutional and retail investors. Top institutional investors include Evermore Global Advisors LLC (6.72%), Russell Investments Group Ltd. (0.76%), Nuveen Asset Management LLC (0.60%), Charles Schwab Investment Management Inc. (0.55%), Bridgeway Capital Management Inc. (0.53%) and Strs Ohio (0.44%). Company insiders that own Enzo Biochem stock include Bruce A Hanna, Discovery Fund Lp Harbert, Elazar Rabbani, Harbert Management Corp and Peter J Iv Clemens.
View institutional ownership trends for Enzo Biochem

Which major investors are selling Enzo Biochem stock?

ENZ stock was sold by a variety of institutional investors in the last quarter, including Evermore Global Advisors LLC, Bridgeway Capital Management Inc., Corrado Advisors LLC, Two Sigma Advisers LP, and UBS Group AG.
View insider buying and selling activity for Enzo Biochem

Which major investors are buying Enzo Biochem stock?

ENZ stock was acquired by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Nuveen Asset Management LLC, Goldman Sachs Group Inc., Strs Ohio, WINTON GROUP Ltd, California Public Employees Retirement System, Integrated Wealth Concepts LLC, and Charles Schwab Investment Management Inc.. Company insiders that have bought Enzo Biochem stock in the last two years include Bruce A Hanna, Discovery Fund Lp Harbert, Elazar Rabbani, Harbert Management Corp, and Peter J Iv Clemens.
View insider buying and selling activity for Enzo Biochem

How do I buy shares of Enzo Biochem?

Shares of ENZ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Enzo Biochem's stock price today?

One share of ENZ stock can currently be purchased for approximately $2.09.

How big of a company is Enzo Biochem?

Enzo Biochem has a market capitalization of $100.09 million and generates $81.17 million in revenue each year. Enzo Biochem employs 460 workers across the globe.

What is Enzo Biochem's official website?

The official website for Enzo Biochem is www.enzo.com.

How can I contact Enzo Biochem?

Enzo Biochem's mailing address is 527 Madison Ave., New York NY, 10022. The medical research company can be reached via phone at 212-583-0100.

This page was last updated on 9/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.